Skip to content
Homepage
Author:
Spyre Therapeutics, Inc.
Posted Date:
July 2, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc.
July 2, 2026
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Spyre Therapeutics, Inc.
June 15, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc.
June 5, 2026
